Last reviewed · How we verify

Azstarys — Competitive Intelligence Brief

Azstarys (SERDEXMETHYLPHENIDATE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Azstarys (SERDEXMETHYLPHENIDATE) — Commcave Therapeutics Sa. Azstarys increases levels of dopamine and norepinephrine in the brain to help regulate attention and impulse control.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Azstarys TARGET SERDEXMETHYLPHENIDATE Commcave Therapeutics Sa marketed 2021-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azstarys — Competitive Intelligence Brief. https://druglandscape.com/ci/serdexmethylphenidate. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: